Scientific Reports (Mar 2024)

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses

  • Tomoka Matsuura,
  • Wakaba Fukushima,
  • Yu Nakagama,
  • Yasutoshi Kido,
  • Tetsuo Kase,
  • Kyoko Kondo,
  • Natsuko Kaku,
  • Kazuhiro Matsumoto,
  • Asae Suita,
  • Emiko Mukai,
  • Yuko Nitahara,
  • Ayako Konishi,
  • Ayane Kasamatsu,
  • Sachie Nakagama,
  • Etsuko Nakagami-Yamaguchi,
  • Satoko Ohfuji,
  • Yukihiro Kaneko,
  • Akira Kaneko,
  • Hiroshi Kakeya,
  • Yoshio Hirota

DOI
https://doi.org/10.1038/s41598-024-57931-0
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 13

Abstract

Read online

Abstract To evaluate the antibody response following the initial four doses of mRNA vaccines (BNT162b2 or mRNA-1273) in SARS-CoV-2-naïve healthy adults and investigate factors influencing antibody titer increases, this prospective cohort study was conducted in Japan from March 2021. The study included participants who received either the 1st and 2nd doses (n = 467), 3rd dose (n = 157), or 4th dose (n = 89). Blood samples were collected before and up to 6 months after each dose, and anti-receptor-binding domain antibody levels were measured. Multivariate analysis (usin multiple linear regression or linear mixed models) revealed several factors significantly associated with higher post-vaccination antibody levels, including mRNA-1273 vaccine (after the 1st and 2nd dose), male gender (after the 3rd and 4th doses), younger age (after the 1st and 2nd dose), non-smoking status (after the 2nd dose), non-use of immunosuppressive agents (after the 1st dose), higher pre-vaccination antibody titers (after the 2nd, 3rd, and 4th doses), and higher post-vaccination fever (after the 2nd and 4th doses). Furthermore, longer intervals since the last dose were significantly associated with higher antibody levels after the 3rd and 4th doses. These findings provide valuable insights for optimizing vaccination strategies.